Skip to content
← Full study record

NCT00258310 · OUTCOME

Overall Survival

Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo · Source last updated 2023-03-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Within 3 years of end of study

What was measured

Estimated time from study entry to death from any cause

Analysis population: Entire study population

Groups in this outcome

Capecitabine

Capecitabine 1000mg/day for one year capecitabine adjuvant therapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Capecitabine33

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
CapecitabineNANot reportedNANANeither the median nor the 95% confidence interval can be calculated because there were too few deaths.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Neither the median nor the 95% confidence interval can be calculated because there were too few deaths.
        group Id
        OG000
        lower Limit
        NA
        upper Limit
        NA
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      33
    units
    Participants
description
Estimated time from study entry to death from any cause
dispersion Type
95% Confidence Interval
groups
  1. description
    Capecitabine 1000mg/day for one year capecitabine adjuvant therapy
    id
    OG000
    title
    Capecitabine
param Type
MEDIAN
population Description
Entire study population
reporting Status
POSTED
time Frame
Within 3 years of end of study
title
Overall Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice